Literature DB >> 22861358

Developments in rabies vaccines.

D J Hicks1, A R Fooks, N Johnson.   

Abstract

The development of vaccines that prevent rabies has a long and distinguished history, with the earliest preceding modern understanding of viruses and the mechanisms of immune protection against disease. The correct application of inactivated tissue culture-derived vaccines is highly effective at preventing the development of rabies, and very few failures are recorded. Furthermore, oral and parenteral vaccination is possible for wildlife, companion animals and livestock, again using inactivated tissue culture-derived virus. However, rabies remains endemic in many regions of the world and causes thousands of human deaths annually. There also remain no means of prophylaxis for rabies once the virus enters the central nervous system (CNS). One reason for this is the poor immune response within the CNS to infection with rabies virus (RABV). New approaches to vaccination using modified rabies viruses that express components of the innate immune system are being applied to this problem. Preliminary reports suggest that direct inoculation of such viruses could trigger an effective anti-viral response and prevent a fatal outcome from RABV infection.
© 2012 Crown copyright. Clinical and Experimental Immunology © 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22861358      PMCID: PMC3444995          DOI: 10.1111/j.1365-2249.2012.04592.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  Growth of rabies virus in non-nervous tissue culture.

Authors:  R E KISSLING
Journal:  Proc Soc Exp Biol Med       Date:  1958-06

2.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.

Authors:  I Seif; P Coulon; P E Rollin; A Flamand
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence.

Authors:  C Prehaud; P Coulon; F LaFay; C Thiers; A Flamand
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.

Authors:  Milosz Faber; Rojjanaporn Pulmanausahakul; Suchita S Hodawadekar; Sergei Spitsin; James P McGettigan; Matthias J Schnell; Bernhard Dietzschold
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Completion of the rabies virus genome sequence determination: highly conserved domains among the L (polymerase) proteins of unsegmented negative-strand RNA viruses.

Authors:  N Tordo; O Poch; A Ermine; G Keith; F Rougeon
Journal:  Virology       Date:  1988-08       Impact factor: 3.616

6.  Growth characteristics of rabies virus in primary chick embryo cells.

Authors:  A Kondo
Journal:  Virology       Date:  1965-10       Impact factor: 3.616

7.  Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States.

Authors:  Sharon L Messenger; Jean S Smith; Charles E Rupprecht
Journal:  Clin Infect Dis       Date:  2002-08-28       Impact factor: 9.079

8.  Chimeric lyssavirus glycoproteins with increased immunological potential.

Authors:  C Jallet; Y Jacob; C Bahloul; A Drings; E Desmezieres; N Tordo; P Perrin
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Bat rabies in the United States and Canada from 1950 through 2007: human cases with and without bat contact.

Authors:  Gaston De Serres; Frédéric Dallaire; Mathieu Côte; Danuta M Skowronski
Journal:  Clin Infect Dis       Date:  2008-05-01       Impact factor: 9.079

View more
  22 in total

Review 1.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

2.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development.

Authors:  Shimao Zhu; Hui Li; Chunhua Wang; Farui Luo; Caiping Guo
Journal:  J Neurovirol       Date:  2015-05-21       Impact factor: 2.643

4.  Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Authors:  Ravish H S; Akash Khobragade; Durga Satapathy; Monica Gupta; Surendra Kumar; Vinay Bhomia; Ramasubramanian V; Maharshi Desai; Ashok Dilipkumar Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

5.  Recombinant adeno-associated virus serotype 9 AAV-RABVG expressing a Rabies Virus G protein confers long-lasting immune responses in mice and non-human primates.

Authors:  Chenjuan Shi; Li Tian; Wenwen Zheng; Yelei Zhu; Peilu Sun; Lele Liu; Wenkai Liu; Yanyan Song; Xianzhu Xia; Xianghong Xue; Xuexing Zheng
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

6.  Carbohydrates: Binding Sites and Potential Drug Targets for Neural-Affecting Pathogens.

Authors:  Cara-Lynne Schengrund
Journal:  Adv Neurobiol       Date:  2023

Review 7.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

Review 8.  Guillain-Barré syndrome in Colombia: where do we stand now?

Authors:  María P Mahecha; Ernesto Ojeda; Daniel A Vega; Juan C Sarmiento-Monroy; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 9.  Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present.

Authors:  Kiran Teresa Thakur; Samantha Epstein; Amanda Bilski; Alanna Balbi; Amelia K Boehme; Thomas H Brannagan; Sarah Flanagan Wesley; Claire S Riley
Journal:  Neurology       Date:  2021-09-02       Impact factor: 9.910

10.  Outer membrane proteins of Salmonella typhimurium as an adjuvant in rabies vaccine.

Authors:  Iman Ibrahim Negm; Yasser M Ragab; Aly Fahmy Mohamed
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.